UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.400-401

2019

Volltextzugriff (PDF)

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours

European journal of cancer (1990), 2013-10, Vol.49 (15), p.3219-3228

2013

Volltextzugriff (PDF)

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Annals of oncology, 2019-07, Vol.30, p.iv26-iv26

2019

Volltextzugriff (PDF)

Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii417-viii417

2018

Volltextzugriff (PDF)

Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer

Annals of oncology, 2018-10, Vol.29, p.viii412-viii413

2018

Volltextzugriff (PDF)

Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy

Annals of oncology, 2018-10, Vol.29, p.viii416-viii417

2018

Volltextzugriff (PDF)

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial

Hematological oncology, 2019-06, Vol.37 (S2), p.65-66

2019

Volltextzugriff (PDF)

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES

Hematological oncology, 2019-06, Vol.37 (S2), p.213-214

2019

Volltextzugriff (PDF)

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.214-216

2019

Volltextzugriff (PDF)

Localization of Fanconi Anemia C Protein to the Cytoplasm of Mammalian Cells

Proceedings of the National Academy of Sciences - PNAS, 1994-08, Vol.91 (17), p.7975-7979

Youssoufian, Hagop

1994

Volltextzugriff (PDF)

195 Intramuscular Electroporation of an Optimized RheoSwitch®-regulated Interferon Alpha Plasmid Transgene Shows Long Term Persistence in Vivo: Implications for Therapy of Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.59-59

2012

Volltextzugriff (PDF)

943TiP PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)

Annals of oncology, 2023-10, Vol.34, p.S592-S592

2023

Volltextzugriff (PDF)

Fanconi anaemia proteins: Major roles in cell protection against oxidative damage

BioEssays, 2003-06, Vol.25 (6), p.589-595

2003

Volltextzugriff (PDF)

DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.69-70

2017

Volltextzugriff (PDF)

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Volltextzugriff (PDF)

Structure, function, and activation of the erythropoietin receptor

Blood, 1993-05, Vol.81 (9), p.2223-2236

1993

Volltextzugriff (PDF)

1033P First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors

Annals of oncology, 2023-10, Vol.34, p.S627-S628

2023

Volltextzugriff (PDF)

640P A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301): Initial results

Annals of oncology, 2023-10, Vol.34, p.S452-S452

2023

Volltextzugriff (PDF)

Fanconi anemia and breast cancer: what's the connection?

Nature genetics, 2001-04, Vol.27 (4), p.352-353

Youssoufian, Hagop

2001

Volltextzugriff (PDF)

Mechanisms and consequences of somatic mosaicism in humans

Nature reviews. Genetics, 2002-10, Vol.3 (10), p.748-758

2002

Volltextzugriff (PDF)

1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer

Annals of oncology, 2021-09, Vol.32, p.S1050-S1051

2021

Volltextzugriff (PDF)

918 Correlative analyses of phase 1b study of navicixizumab plus paclitaxel in patients with platinum resistant ovarian cancer using xerna™ TME panel

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A283-A283

2021

Volltextzugriff (PDF)

Localization of Anticoagulantly Active Heparan Sulfate Proteoglycans in Vascular Endothelium: Antithrombin Binding on Cultured Endothelial Cells and Perfused Rat Aorta

The Journal of cell biology, 1990-09, Vol.111 (3), p.1293-1304

1990

Volltextzugriff (PDF)

Cell cycle-dependent expression and nucleolar localization of hCAP-H

Molecular biology of the cell, 2001-11, Vol.12 (11), p.3527-3537

2001

Volltextzugriff (PDF)

381TiPTRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(147)

Publikationsform

Artikel
(153)

Sprache

Englisch
(153)

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Life Sciences & Biomedicine
(64)
Humans
(60)
Biological And Medical Sciences
(41)
Animals
(30)
Mutation
(23)
Fundamental And Applied Biological Sciences. Psychology
(21)
Male
(21)
Medical Sciences
(20)
Dna-Binding Proteins
(19)
Cell Cycle Proteins
(18)
Fanconi Anemia Complementation Group Proteins
(18)
Genetics & Heredity
(18)
Mice
(18)
Nuclear Proteins
(17)
Proteins - Genetics
(17)
Female
(16)
Base Sequence
(15)
Biochemistry & Molecular Biology
(15)
Hematology
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors

Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer

Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Localization of Fanconi Anemia C Protein to the Cytoplasm of Mammalian Cells

195 Intramuscular Electroporation of an Optimized RheoSwitch®-regulated Interferon Alpha Plasmid Transgene Shows Long Term Persistence in Vivo: Implications for Therapy of Cancer

943TiP PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)

Fanconi anaemia proteins: Major roles in cell protection against oxidative damage

DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Structure, function, and activation of the erythropoietin receptor

1033P First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors

640P A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301): Initial results

Fanconi anemia and breast cancer: what's the connection?

Mechanisms and consequences of somatic mosaicism in humans

1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer

918 Correlative analyses of phase 1b study of navicixizumab plus paclitaxel in patients with platinum resistant ovarian cancer using xerna™ TME panel

Localization of Anticoagulantly Active Heparan Sulfate Proteoglycans in Vascular Endothelium: Antithrombin Binding on Cultured Endothelial Cells and Perfused Rat Aorta

Cell cycle-dependent expression and nucleolar localization of hCAP-H

381TiPTRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Suchergebnisse filtern